Cancer Prognostic Resources: A Systematic Review and Central Repository of Webbased Cancer Prognostic Calculators
|
|
|
- Lesley Phillips
- 7 years ago
- Views:
Transcription
1 Cancer Prognostic Resources: A Systematic Review and Central Repository of Webbased Cancer Prognostic Calculators 20 th Annual HMORN Conference Phoenix, AZ April 3, 2014 Presenter: Michelle Henton, MA Kaiser Permanente Colorado, Institute for Health Research Co-authors: Borsika Rabin, PhD, MPH, Bridget Gaglio, PhD, MPH, Tristan Sanders, MPH, Larissa Nekhlyudov, MD, MPH, Alfred Marcus, PhD, Sheana Bull, PhD, MPH, James W. Dearing, PhD Acknowledgements: Funding for this research was provided through the National Cancer Institute (NCI Grant # 1P20 CA )
2 Communicating cancer prognosis Patient provider communication in the cancer context involves highly complex information. Cancer prognosis is a lead topic of interest for patients, caregivers, and clinicians. Prognostic information can support multiple processes and fill various needs. Efficient communication of prognosis can be challenging. Providers use various resources and different levels of specificity when communicating about prognosis with their patients. Web-based tools have tremendous potential and increasing role in supporting patient-centered communication around various topics including cancer care.
3 Research questions What are the characteristics of currently available web-based cancer prognostic tools? AND Can these tools support patient-provider communication about cancer prognosis?
4 Cancer prognostic tool a definition Cancer prognostic tools (nomograms) are designed to support decision making including treatment decisions through providing cancer outcome predications that take diverse patient characteristics into account. Review focuses on tools that are: English version Interactive Focus on cancer Web-based Include at least one of the following measures: Cancer or non-cancer specific mortality/overall survival Disease free survival/recurrence Clinical response to treatment Progression free survival/spread Cancer therapy induced side effects
5 Methods: Review process Web search Literature search Expert input Tools identified (n=36) Tools excluded due to lack of access (n=6) Tools reviewed for eligibility (n=30) Tools excluded due to ineligibility (no focus on required outcomes) (n=8) Tools included and abstracted (n=22)
6 Methods: Variables of interest Variables of interest: 1. General characteristics and purpose Goal, cancer sites, intended user, disclaimer, etc. 2. Data Algorithm, validation, data source, etc. 3. Input factors Demographics, cancer characteristics, comorbidities, etc. 4. Output measures Survival measures, quality of life, spread, etc. 5. Display of data Visual display, output content and format, etc. 6. Usability Print/save function, missing data, FAQ, etc. 7. Patient-centeredness Health literacy/numeracy, interpretation, connection to EHR, etc. 8. Other specifications Access, cost, accessibility, etc.
7 Cancer Prognostic Tools Tool Name Brief Name Developer Adjuvant Online Adjuvant Adjuvant! Inc. AJCC Individualized Melanoma Patient Outcome Prediction Tools AJCC American Joint Committee on Cancer Artificial Neural Networks in Prostate Cancer ANN Institute for Dynamic Educational Advancement Biochemical Recurrence-free Survival Prediction Model BioChemical Duke Prostate Center CancerMath UCSF Capra Score Cancer Survival Query System Disease free survival calculator for EBRT, brachytherapy and combinations of the two FinProg Online Nomograms for predictiong survival of GBM patients CancerMath Capra CSQS EBRT FinProg GBM CancerMath.net University of California San Francisco Medical Center National Cancer Institute Professor Les Bradbury The FinProg Research Group European Organisation for Research and Treatment of Cancer
8 Tool Name Brief Name Developer IBTR Breast Cancer Module Version 2.0 IBTR Unknown Knight Cancer Institute Survival Prediction Tools Lerner Research Institute Risk Calculators KCI Lerner Knight Cancer Institute at Oregon Health and Science University Cleveland Clinic - Lerner Research Institute MAASTRO prediction website MD Anderson Clinical calculators Memorial Sloan-Kettering Prediction Tools University of Montreal - Nomograms MAASTRO MD Anderson MSK Nomograms MAASTRO Clinic MD Anderson Cancer Center Memorial Sloan Kettering Cancer Center University of Montreal Mayo Clinic Adjuvant Tool (Numeracy) Numeracy Mayo Clinic Prognostigram QxMD Calculate Calculator for Estimating Overall Life Expectancy and Lifetime Risk for Prostate Cancer Death in Newly Diagnosed Men Managed without Definitive Local Therapy Prognostigram QxMD Roswell Park Washington University in St. Louis QxMD Roswell Park Cancer Institute
9 Findings: General characteristics and purpose At the time of the review (2012), a total of 22 tools reviewed and abstracted with 107 stand alone calculators and 89 unique cancer sites More tools have been added to the site Great variation in the number of calculators (min: 1; max: 22) the number of cancer sites (min: 1; max: 84) Top five cancer sites: Prostate (n=11) Colorectal (n=10) Breast (n=8) Genitourinary cancers (n=6) Melanoma (n=6)
10 Findings: General characteristics and purpose Purpose: Baseline prognostic information Support treatment decision after diagnosis Decide on benefits for adjuvant therapy Cancer stage: Various limitations (e.g., no metastasis, certain stage) Intended user: Most for cancer specialists/physicians Only 4 tools mentions patients as potential users
11 Findings: Data Data source: Population-based Clinic-based Mixed All except one reported validation of algorithm for at least one calculator Reporting of algorithms used by tools was variable
12 Findings: Input factors Input domain Example # of tools included Cancer characteristics Tumor size, nodal status, grade Demographic characteristics Age, gender, marital status Co-morbidities Specific/generic 9 Therapy impact Chemo, Radiation 19 Genetic characteristics ER/PR, HER2, HBOC syndrome 5 Modifiable risk factors Smoking status 2
13 Findings: Output measures Measure # of tools included Cancer specific mortality/survival 17 Disease/Progression free survival 16 Non-cancer specific survival 4 Clinical response to treatment 2 Therapy-induced side effects 2
14 Findings: Usability Function # of tools included Print/Save/ 6 FAQ for user guide 8 Documentation 5 Technical assistance 9 Time to use Average > 1 min
15 Systematic review of cancer prognostic tools Rabin BA, Gaglio B, Sanders T, Nekhlyudov L, Dearing JW, Bull S, Glasgow RE, Marcus A. Predicting cancer prognosis using interactive online tools: A systematic review and implications for cancer care providers. Cancer Epidemiology, Biomarkers, & Prevention, 2013:22:1625
16 Cancer Prognostic Resources Website
17 Cancer Prognostic Resources Website: View All Tools
18 Cancer Prognostic Resources Website: Compare Tools by Cancer Site
19 Cancer Prognostic Resources Website: Search Tools
20 Cancer Prognostic Resources Website: Individual Tool Details
21 Cancer Prognostic Resources Website: Submit a Tool
22 Cancer Prognostic Resources Website Website: Facebook: facebook.com/cancercalculators Twitter: twitter.com/cancercalc
23
Designing for Dissemination and Implementation: A pragmatic case study for the development and evaluation of a cancer prognostic tool
Designing for Dissemination and Implementation: A pragmatic case study for the development and evaluation of a cancer prognostic tool Insights and Innovation in Improving Health CRISP Seminar Series Borsika
Individual Prediction
Individual Prediction Michael W. Kattan, Ph.D. Professor of Medicine, Epidemiology and Biostatistics, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Chairman, Department
Analysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data
The 2014 Cancer Program Annual Public Reporting of Outcomes/Annual Site Analysis Statistical Data from 2013 More than 70 percent of all newly diagnosed cancer patients are treated in the more than 1,500
Alaska Comprehensive Cancer Control Plan 2011-15
Alaska Comprehensive Cancer Control Plan 2011-15 Alaska Comprehensive Cancer Plan 2011-2015 STATE of ALASKA Department of Health and Social Services ALASKA Comprehensive Cancer Partnership Prevention Promotion
Robert Bristow MD PhD FRCPC
Robert Bristow MD PhD FRCPC Clinician-Scientist and Professor, Radiation Oncology and Medical Biophysics, University of Toronto and Ontario Cancer Institute/ (UHN) Head, PMH-CFCRI Prostate Cancer Research
Session 5 Panel Discussion
Session 5 Panel Discussion Question: How can epidemiology help integrate knowledge from basic, clinical and population sciences to accelerate translation from research to practice? Moderator: Muin J. Khoury,
Electronic health records to study population health: opportunities and challenges
Electronic health records to study population health: opportunities and challenges Caroline A. Thompson, PhD, MPH Assistant Professor of Epidemiology San Diego State University Caroline.Thompson@mail.sdsu.edu
Management of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs. Case Study. Surgery. Lumpectomy and Radiation
Management of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs Michael Alvarado, MD Associate Professor of Surgery University of California San Francisco Case Study 59 yo woman with new palpable
Travel Distance to Healthcare Centers is Associated with Advanced Colon Cancer at Presentation
Travel Distance to Healthcare Centers is Associated with Advanced Colon Cancer at Presentation Yan Xing, MD, PhD, Ryaz B. Chagpar, MD, MS, Y Nancy You MD, MHSc, Yi Ju Chiang, MSPH, Barry W. Feig, MD, George
Theories on Metastasis: Innovative Thinking An Advocacy Perspective
Theories on Metastasis: Innovative Thinking An Advocacy Perspective Project LEAD Workshop NBCC Annual Advocacy Conference 2011 Musa Mayer AdvancedBC.org 1 The Big Question If we want to end death from
Colorectal Cancer Screening Behaviors among American Indians in the Midwest
JOURNAL OF HD RP Journal of Health Disparities Research and Practice Volume 4, Number 2, Fall 2010, pp. 35 40 2010 Center for Health Disparities Research School of Community Health Sciences University
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal
Beyond the PSA: Genomic Testing in Localized Prostate Cancer
Beyond the PSA: Genomic Testing in Localized Prostate Cancer Kelvin A. Moses, MD, PhD Vanderbilt University Medical Center Wednesday, December 2, 2015 5:00 p.m. ET/2:00 p.m. PT About ZERO ZERO s mission
Big Data and Oncology Care Quality Improvement in the United States
Big Data and Oncology Care Quality Improvement in the United States Peter P. Yu, MD, FACP, FASCO President, American Society of Clinical Oncology Director of Cancer Research, Palo Alto Medical Foundation
Chapter 2 History of MD Anderson s Tumor Registry
Chapter 2 History of MD Anderson s Tumor Registry Sarah H. Taylor The Tumor Registry Department at The University of Texas MD Anderson Cancer Center is responsible for a database that contains demographic
Report series: General cancer information
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA)
NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA) Merat Esfahani, MD Medical Oncologist, Hematologist Cancer Liaison Physician SwedishAmerican Regional Cancer Center
4/8/13. Pre-test Audience Response. Prostate Cancer 2012. Screening and Treatment of Prostate Cancer: The 2013 Perspective
Pre-test Audience Response Screening and Treatment of Prostate Cancer: The 2013 Perspective 1. I do not offer routine PSA screening, and the USPSTF D recommendation will not change my practice. 2. In light
Disparities in Stage at Diagnosis, Survival, and Quality of Cancer Care in California by Source of Health Insurance
Disparities in Stage at Diagnosis, Survival, and Quality of Cancer Care in California by Source of Health Insurance Acknowledgements and Disclaimer The collection of cancer incidence data used in this
Patient and Caregiver Resources
Patient and Caregiver Resources Your best resource in the fight against cancer Visit NCCN.org/patients Patient Education Payment Assistance Advocacy and Support Groups Patient and Caregiver Resources Your
Cancer Treatment Planning: A Means to Deliver Quality, Patient-Centered Care
Cancer Treatment Planning: A Means to Deliver Quality, Patient-Centered Care Patricia A. Ganz, M.D. Jonsson Comprehensive Cancer Center UCLA Schools of Medicine & Public Health Overview of Presentation
Does Radiation Treatment of Prostate Cancer Increase Risk for Rectal Cancer? The Perfect Storm
NAACCR Conference, Austin, TX June 13, 2013 In Collaboration with: Does Radiation Treatment of Prostate Cancer Increase Risk for Rectal Cancer? The Perfect Storm John W. Morgan, DrPH, CPH, Brice Jabo,
Oncology Nursing Society Annual Progress Report: 2008 Formula Grant
Oncology Nursing Society Annual Progress Report: 2008 Formula Grant Reporting Period July 1, 2011 June 30, 2012 Formula Grant Overview The Oncology Nursing Society received $12,473 in formula funds for
New ACSM Specialty Certification
New ACSM Specialty Certification The American College of Sports Medicine (ACSM) is pleased to announce the offering of a new specialty certification. This certification is an industry-first for professionals
Optimizing Adoption of Advanced Technology to Achieve High Value Cancer Care: The Case of Proton Therapy ECRI NCI Conference November 17, 2015
Optimizing Adoption of Advanced Technology to Achieve High Value Cancer Care: The Case of Proton Therapy ECRI NCI Conference November 17, 2015 Justin E. Bekelman, MD Associate Professor, Radiation Oncology
Recommendations on Disease Management for Patients with Advanced HER2-Positive Breast Cancer and Brain Metastases
Recommendations on Disease Management for Patients with Advanced HER2-Positive Breast Cancer and Brain Metastases Clinical Practice Guideline www.asco.org/guidelines/her2brainmets American Society of Clinical
Newly Diagnosed Prostate Cancer: Understanding Your Risk
Newly Diagnosed Prostate Cancer: Understanding Your Risk When the urologist calls with the life-changing news that your prostate biopsy is positive for prostate cancer, an office appointment is made to
The Contribution of large Healthcare Systems to Improving Treatment for Patients with Rare Diseases
Uniting Rare Diseases Advancing Rare Disease Research: The Intersection of Patient Registries, Biospecimen Repositories and Clinical Data Keynote address: The Contribution of large Healthcare Systems to
STRATEGIES FOR ASSESSING THE PATIENT-LEVEL ECONOMIC IMPACT OF CANCER DIAGNOSIS
Cumulative % Increase 5/20/2015 STRATEGIES FOR ASSESSING THE PATIENT-LEVEL ECONOMIC IMPACT OF CANCER DIAGNOSIS ISPOR 20 th Annual International Meeting -- Philadelphia, PA May 20 th 2015 Workshop Moderators:
Gleason Score. Oncotype DX GPS. identified for. about surveillance. time to get sophisticated
patient: MARK SMITH PSA 6.2 Gleason Score 6 Oncotype DX GPS 8 identified for active surveillance time to get sophisticated about surveillance Accurate prediction of prostate cancer risk is needed at the
2010 SITE REPORT St. Joseph Hospital PROSTATE CANCER
2010 SITE REPORT St. Joseph Hospital PROSTATE CANCER Humboldt County is located on the Redwood Coast of Northern California. U.S census data for 2010 reports county population at 134,623, an increase of
Standardized Representation for Electronic Health Record-Driven Phenotypes
Standardized Representation for Electronic Health Record-Driven Phenotypes April 8, 2014 AMIA Joint Summits for Translational Research Rachel L. Richesson, PhD Shelley A. Rusincovitch Michelle M. Smerek
Normal values of IGF1 and IGFBP3. Kučera R., Vrzalová J., Fuchsová R., Topolčan O., Tichopád A.
Normal values of IGF1 and IGFBP3 Kučera R., Vrzalová J., Fuchsová R., Topolčan O., Tichopád A. Agenda of the presentation IGF1 and IGFBP3 basic characteristic Why normal values Groups of the persons and
Use of stents in esophageal cancer" Hans Gerdes, M.D. Director, GI Endoscopy Unit Memorial Sloan-Kettering Cancer Center
Use of stents in esophageal cancer" Hans Gerdes, M.D. Director, GI Endoscopy Unit Memorial Sloan-Kettering Cancer Center Features of esophageal cancer Esophageal cancer is an abnormal growth that arises
Sponsorship Proposal 5K RUN/WALK. to benefit early lung cancer detection research at University of Colorado Cancer Center
Sponsorship Proposal 5K RUN/WALK to benefit early lung cancer detection research at University of Colorado Cancer Center A NATIONAL CANCER INSTITUTE-DESIGNATED Lung cancer is the leading cause of cancer
Epidemiology, Staging and Treatment of Lung Cancer. Mark A. Socinski, MD
Epidemiology, Staging and Treatment of Lung Cancer Mark A. Socinski, MD Associate Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive Cancer Center University of
Lung Cancer. Public Outcomes Report. Submitted by Omar A. Majid, MD
Public Outcomes Report Lung Cancer Submitted by Omar A. Majid, MD Lung cancer is the most common cancer-related cause of death among men and women. It has been estimated that there will be 226,1 new cases
Prostate Cancer 2014
Prostate Cancer 2014 Eric A. Klein, M.D. Chairman Glickman Urological and Kidney Institute Professor of Surgery Cleveland Clinic Lerner College of Medicine Incidence rates, US Men Mortality Rates, US Men
Risk Assessment and Screening Tools November 17, 2010
Risk Assessment and Screening Tools November 17, 2010 Cecelia Bellcross Posted in the Resource Repository at: http://www.resourcerepository.org/documents/2073/riskassessmentandscreeningtool s/ Cecelia
Table 16a Multiple Myeloma Average Annual Number of Cancer Cases and Age-Adjusted Incidence Rates* for 2002-2006
Multiple Myeloma Figure 16 Definition: Multiple myeloma forms in plasma cells that are normally found in the bone marrow. 1 The plasma cells grow out of control and form tumors (plasmacytoma) or crowd
Religious and Spiritual Issues in African Americans at Increased Risk for Cancer
Religious and Spiritual Issues in African Americans at Increased Risk for Cancer Chanita Hughes Halbert, Ph.D. Department of Psychiatry and Abramson Cancer Center Populations at Increased Risk for Developing
Prostate Cancer. Treatments as unique as you are
Prostate Cancer Treatments as unique as you are UCLA Prostate Cancer Program Prostate cancer is the second most common cancer among men. The UCLA Prostate Cancer Program brings together the elements essential
2016 Physician Quality Reporting System Data Collection Form: Oncology (for patients aged 18 and older)
2016 Physician Quality Reporting System Data Collection Form: Oncology (for patients aged 18 and older) IMPTANT: Any measure with a 0% performance rate (100% for inverse measures) is not considered satisfactory
Us TOO University Presents: Understanding Diagnostic Testing
Us TOO University Presents: Understanding Diagnostic Testing for Prostate Cancer Patients Today s speaker is Manish Bhandari, MD Program moderator is Pam Barrett, Us TOO International Made possible by
Renal Cell Carcinoma (Event Driven)
Brochure More information from http://www.researchandmarkets.com/reports/2365661/ Renal Cell Carcinoma (Event Driven) Description: The Renal Cell Carcinoma market is highly lucrative. We anticipate that
Section 8» Incidence, Mortality, Survival and Prevalence
Section 8» Incidence, Mortality, Survival and Prevalence 8.1. Description of Statistics Reported This section focuses on the regional distribution of cancer with data derived from the BC Cancer Registry
Controversites: Screening for Prostate Cancer in Older Adults
Controversites: Screening for Prostate Cancer in Older Adults William Dale, MD, PhD University of Chicago Sections of Geriatrics & Palliative Medicine and Hematology/Oncology Director, Specialized Oncology
An Online Continuing Education Module to Support Evidence-based Clinical Guidelines
An Online Continuing Education Module to Support Evidence-based Clinical Guidelines Craig Robbins, MD, David Price, MD, Sarah Shimer, Helen Morant, MD, Gladys Tom, Carolyn Simpkins, MD About Kaiser Permanente
October is Breast Cancer Awareness Month!
October is Breast Cancer Awareness Month! A STUDY OF CHARACTERISTICS AND MANAGEMENT OF BREAST CANCER IN TAIWAN Eric Kam-Chuan Lau, OMS II a, Jim Yu, OMSII a, Christabel Moy, OMSII a, Jian Ming Chen, MD
Clinical Decision Support (CDS) to improve colorectal cancer screening
Clinical Decision Support (CDS) to improve colorectal cancer screening NIH Collaboratory Grand Rounds Sept 26, 2014 Presented by: Tim Burdick MD MSc OCHIN Chief Medical Informatics Officer Adjunct Associate
Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy
Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy W. Fraser Symmans, M.D. Associate Professor of Pathology UT M.D. Anderson Cancer Center Pathologic Complete Response (pcr) Proof
UICC World Cancer Congress. Cancer Staging and Quality of Care
UICC World Cancer Congress August 27 30, 2012, Montreal CANCER STAGE: A neglected cornerstone of Cancer Control Cancer Staging and Quality of Care Christian Wittekind Institut für Pathologie UKL 1 Agenda!
Metastatic Breast Cancer...
DIAGNOSIS: Metastatic Breast Cancer... What Does It Mean For You? A diagnosis of metastatic breast cancer can be frightening. It raises many questions and reminds us of days past when cancer was such a
Saving healthcare costs by implementing new genetic risk tests for early detection of cancer and prevention of cardiovascular diseases
Saving healthcare costs by implementing new genetic risk tests for early detection of cancer and prevention of cardiovascular diseases Jeff Gulcher, MD PhD Chief Scientific Officer and co-founder decode
UW Medicine Integrated Mental Health Care. Laura Collins MSW, Darcy Jaffe ARNP Jürgen Unützer, MD, MPH, MA
UW Medicine Integrated Mental Health Care Laura Collins MSW, Darcy Jaffe ARNP Jürgen Unützer, MD, MPH, MA Why Behavioral Health Care in Primary Care? 1. Access to care: Serve patients where they are 2.
The Genetics of Early- Onset Breast Cancer. Cecelia Bellcross, Ph.D., M.S.,C.G.C. Department of Human Genetics Emory University School of Medicine
The Genetics of Early- Onset Breast Cancer Cecelia Bellcross, Ph.D., M.S.,C.G.C. Department of Human Genetics Emory University School of Medicine All cancers are genetic BUT Not all cancers are hereditary
A New Biomarker in Prostate Cancer Care: Oncotype Dx. David M Albala, MD Chief of Urology Crouse Hospital Syracuse, NY
A New Biomarker in Prostate Cancer Care: Oncotype Dx David M Albala, MD Chief of Urology Crouse Hospital Syracuse, NY Learning Objectives Review the current challenges in the prediction and prognosis of
Prostate Cancer. Racial Differences in Prostate Cancer Treatment Outcomes. Prostate Cancer Epidemiology. Prostate Cancer Epidemiology
Prostate Cancer Anatomy Paul A. Godley, MD, PhD Cancer Incidence, Males Prostate Cancer Epidemiology 24 Estimated New Cancer Cases Melanoma 29,9 Oral 18,55 Stomach 13,4 Leukemias 19,2 Kidney 22,8 Lymphomas
Number. Source: Vital Records, M CDPH
Epidemiology of Cancer in Department of Public Health Revised April 212 Introduction The general public is very concerned about cancer in the community. Many residents believe that cancer rates are high
MANCHESTER Lung Cancer Screening Program Dartmouth-Hitchcock Manchester 100 Hitchcock Way Manchester, NH 03104 (603) 695-2850
LEBANON Lung Cancer Screening Program One Medical Center Drive Lebanon, NH 03756 (603) 650-4400 (866) 966-1601 Toll-free cancer.dartmouth.edu/lungscreening MANCHESTER Lung Cancer Screening Program Dartmouth-Hitchcock
Secondary Uses of Data for Comparative Effectiveness Research
Secondary Uses of Data for Comparative Effectiveness Research Paul Wallace MD Director, Center for Comparative Effectiveness Research The Lewin Group Paul.Wallace@lewin.com Disclosure/Perspectives Training:
Use of Androgen Deprivation Therapy (ADT) in Localized Prostate Cancer
Use of Androgen Deprivation Therapy (ADT) in Localized Prostate Cancer Adam R. Kuykendal, MD; Laura H. Hendrix, MS; Ramzi G. Salloum, PhD; Paul A. Godley, MD, PhD; Ronald C. Chen, MD, MPH No conflicts
Early mortality rate (EMR) in Acute Myeloid Leukemia (AML)
Early mortality rate (EMR) in Acute Myeloid Leukemia (AML) George Yaghmour, MD Hematology Oncology Fellow PGY5 UTHSC/West cancer Center, Memphis, TN May,1st,2015 Off-Label Use Disclosure(s) I do not intend
Cancer Communication & Care Plan - We Learned How We Work
Communication & Care Plan for Breast Cancer Treatment Creating a Tool for Patient-Centered Care Laura Esserman, MD, MBA Director, UCSF Carol Franc Buck Breast Care Center Director, Cancer Center Clinical
Colorado Cancer Coalition Priorities: 2016 2018
Option 3 of 10: Screening & Early Detection: Screening Rates Presenter: Toni Panetta, MA, Director of Mission Programs, Susan G. Komen Colorado Goal 5: Objective 5.1: Objective 5.2 Focus Area: Focus Area:
Medical Marijuana Use in Patients with History of SCCHN Treated with Radiotherapy
HEALTH SERVICES RESEARCH Assessment the Impact of Real-time Tumor Tracking & Reduced Planning Target Volume Margins on Quality-of-Life in Prostate Cancer Patients Treatment with Intensity Modulated Radiotherapy
Oncology Nursing Society Annual Progress Report: 2008 Formula Grant
Oncology Nursing Society Annual Progress Report: 2008 Formula Grant Reporting Period July 1, 2009 June 30, 2010 Formula Grant Overview The Oncology Nursing Society received $12,473 in formula funds for
Systemic Therapy for Patients With Advanced HER2-Positive Breast Cancer
Systemic Therapy for Patients With Advanced HER2-Positive Breast Cancer CLINICAL PRACTICE GUIDELINE www.asco.org/guidelines/treather2pos American Society of Clinical Oncology. All rights reserved. Introduction
Finnish Cancer Registry Institute for Statistical and Epidemiological Cancer Research. Survival ratios of cancer patients by area in Finland
Survival ratios of cancer patients by area in Finland Pages 2 14 present the relative survival ratios for patients diagnosed in 2005 2012 and followed-up in 2010 2012 (see Methods p. 15) on different university
Obesity and prostate cancer incidence and survival Elizabeth A. Platz, ScD, MPH
Obesity and prostate cancer incidence and survival Elizabeth A. Platz, ScD, MPH Professor and Martin D. Abeloff, MD Scholar in Cancer Prevention Department of Epidemiology, Johns Hopkins Bloomberg School
Oncology Nurses: Leveraging an Underutilized Communication Resource in Cancer Treatment Planning
Oncology Nurses: Leveraging an Underutilized Communication Resource in Cancer Treatment Planning Surgery Inpatient Care Chemotherapy Radiation Therapy Home Care MARIE BAKITAS, DNSc, APRN, FAAN ASSOCIATE
ABOUT THE DECISION AID. Knowing Your Options: A Decision Aid for Men With Localized Prostate Cancer. Program Information
Program Information Overview Educational Content Acknowledgement of Support Production Release Date and Updating Policy Target Audience BCM Development Team Disclosure (Current Aid, 2011) Method of Participation
Treatment & Research. Treatment & Research
Treatment & Research In March 1990, I became ill while on a trip to Thailand. I was examined and tested and given instructions to go to the emergency room when I arrived at home. In Great Falls, I learned
Effect of Risk and Prognosis Factors on Breast Cancer Survival: Study of a Large Dataset with a Long Term Follow-up
Georgia State University ScholarWorks @ Georgia State University Mathematics Theses Department of Mathematics and Statistics 7-28-2012 Effect of Risk and Prognosis Factors on Breast Cancer Survival: Study
Electronic Oral Health Risk Assessment Tools
SCDI White Paper No. 1074 Approved by ADA Council on Dental Practice May 2013 ADA SCDI White Paper No. 1074 Electronic Oral Health Risk Assessment Tools 2013 Copyright 2013 American Dental Association.
The 4Kscore blood test for risk of aggressive prostate cancer
The 4Kscore blood test for risk of aggressive prostate cancer Prostate cancer tests When to use the 4Kscore Test? Screening Prior to 1 st biopsy Prior to negative previous biopsy Prognosis in Gleason 6
Radiation Therapy for Prostate Cancer: Treatment options and future directions
Radiation Therapy for Prostate Cancer: Treatment options and future directions David Weksberg, M.D., Ph.D. PinnacleHealth Cancer Institute September 12, 2015 Radiation Therapy for Prostate Cancer: Treatment
Genomic Medicine Education Initiatives of the College of American Pathologists
Genomic Medicine Education Initiatives of the College of American Pathologists Debra G.B. Leonard, MD, PhD, FCAP Chair, Personalized Healthcare Committee, CAP Professor of Pathology, Weill Cornell Medical
When the diagnosis is cancer, many people
Hard decisions about cancer 5 tests and treatments to question When the diagnosis is cancer, many people understandably want to pull out all the stops to treat it. But some tests, treatments, and procedures
California HealthCare Foundation Education materials for patients with advanced cancer
California HealthCare Foundation Education materials for patients with advanced cancer The California HealthCare Foundation (CHCF) commissioned research to explore options around the development of patient
Individualized breast cancer follow-up Cost-effectiveness of various programs
Individualized breast cancer follow-up Cost-effectiveness of various programs Jesse van Elteren, MSc Erwin Hans, Associate Professor e.w.hans@utwente.nl Agenda Introduction Method Results Conclusions Co-authors
Bristol Hospital Cancer Care Center 2015 Annual Report
Bristol Hospital Cancer Care Center 2015 Annual Report 2015 Annual Report Cancer Care Center At every point along the path, our team is there, keeping the focus on the most important team member - the
Challenges in assessing disease latency for cancer in environmental epidemiology
Challenges in assessing disease latency for cancer in environmental epidemiology Peggy Reynolds, Ph.D. Case-only Clustering in Mobile Populations Workshop - November 11-12, 2010 Ann Arbor, Michigan Outline
Report with statistical data from 2007
2008 Cancer Program Annual Report with statistical data from 2007 Lake Cumberland Regional Hospital 305 Langdon Streett Somerset, KY 42503 Telephone: 606-679-7441 Fax: 606-678-9919 Cancer Committee Mullai,
Analysis of Population Cancer Risk Factors in National Information System SVOD
Analysis of Population Cancer Risk Factors in National Information System SVOD Mužík J. 1, Dušek L. 1,2, Pavliš P. 1, Koptíková J. 1, Žaloudík J. 3, Vyzula R. 3 Abstract Human risk assessment requires
Case Study: MyCancerJourney Using Predictive Analytics to Empower Treatment Decisions
Case Study: MyCancerJourney Using Predictive Analytics to Empower Treatment Decisions Case Study: MyCancerJourney, Using Predictive Analytics to Empower Treatment Decisions Overview Challenge Risk-adjusted
TABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment...11. Chapter3 ValueandSpending...
CANCER TABLE OF CONTENTS Introduction...1 Chapter1 AdvancesinTreatment...2 Chapter2 MedicinesinDevelopment......11 Chapter3 ValueandSpending......15 Chapter4 Conclusion...22 INTRODUCTION Researchers and
7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
Medical Informatics II
Medical Informatics II Zlatko Trajanoski Institute for Genomics and Bioinformatics Graz University of Technology http://genome.tugraz.at zlatko.trajanoski@tugraz.at Medical Informatics II Introduction
Chinese Medicine for People with Lung Cancer: Treatment Results
Chinese Medicine for People with Lung Cancer: Treatment Results Clinical Advocacy Conference, Commonweal 2012 Michael McCulloch, LAc MPH PhD Pine Street Foundation Historical origins Chinese medicine developed
Measures of Prognosis. Sukon Kanchanaraksa, PhD Johns Hopkins University
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
ENVISIONING THE FUTURE OF DERMATOLOGY THROUGH THE LENS OF MEDICAL INFORMATICS
Is pleased to announce: ENVISIONING THE FUTURE OF DERMATOLOGY THROUGH THE LENS OF MEDICAL INFORMATICS CONFERENCE LOCATION MEMORIAL SLOAN KETTERING CANCER CENTER ROCKEFELLER RESEARCH LABORATORIES BOARD
SUMMARY. Randolph Fillmore, Florida Science Communications
SUMMARY Randolph Fillmore, Florida Science Communications The H. Lee Moffitt Cancer Center held its first Advanced Prostate Cancer Collaboration roundtable discussion November 24, 2008. The roundtable
Treatment Decision Making in Patients with Bladder Cancer
Treatment Decision Making in Patients with Bladder Cancer Donna L Berry, PhD, RN Associate Professor Director-Phyllis F. Cantor Center Dana-Farber Cancer Institute Co-investigators and team Clinician scientists
Next Generation Registries: Project INSPIRE
Next Generation Registries: Project INSPIRE Michael Hogarth, MD, FACP Professor, Internal Medicine Professor, Pathology and Laboratory Medicine UC Davis Health System http://www.hogarth.org Medical Director
Protection for you, your finances & your future!
Group Critical Illness Insurance Protection for you, your finances & your future! AGENDA Who is ACE BCCA s new AD&D The Need for Critical Illness The BCCA CI Program How is the product different Policy
Primary Care Management of Colorectal Cancer
Primary Care Management of Colorectal Cancer Dr. Dan Renouf, Medical Oncologist, BC Cancer Agency Vancouver Centre November 1, 2014 www.fpon.ca Primary Care Management of Colorectal Cancer Survivors Daniel
Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases
I Congresso de Oncologia D Or July 5-6, 2013 Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University
Radiation Therapy in Prostate Cancer Current Status and New Advances
Radiation Therapy in Prostate Cancer Current Status and New Advances Arno J. Mundt MD Professor and Chairman Dept Radiation Oncology Moores Cancer Center UCSD Presentation Welcome Overview of UCSD, Moores
Clinical trial enrollment among older cancer patients
Clinical trial enrollment among older cancer patients Sharon H. Giordano MD, MPH Professor, Health Services Research Mariana Chavez Mac Gregor MD, MSc Assistant Professor, Breast Medical Oncology Department